[Progress in the diagnosis and treatment of childhood AML]

Area of Science:

• Pediatric Hematology/Oncology
• Molecular Diagnostics
• Cancer Genomics

Context:

• Approximately 180 childhood acute myeloid leukemia (AML) cases occur annually in Japan.
• Accurate diagnosis and risk stratification are critical for effective AML treatment.
• Current treatment protocols follow guidelines from the Japanese Society of Pediatric Hematology/Oncology (JSPHO) and the Japan Pediatric Leukemia and Lymphoma Study Group (JPLSG).

Purpose:

• To outline the essential diagnostic methods for childhood AML, including morphology, immunophenotyping, and genetic analyses.
• To describe the current treatment strategies for different subtypes of AML (APL, ML-DS, de novo AML) in Japan.
• To highlight the need for novel therapeutic agents and advanced prognostic analyses using next-generation sequencing for improved outcomes and reduced late complications.

Summary:

• Childhood AML diagnosis in Japan relies on morphology, immunophenotyping, and genetic analyses for differential diagnosis and risk stratification.
• Treatment follows JSPHO guidelines and JPLSG protocols for APL, ML-DS, and de novo AML, with prognoses comparable to international standards.
• Despite good outcomes, advancements in new drugs and next-generation sequencing for prognostic analysis are essential to further improve survival and minimize late treatment effects.

Impact:

• Enhances understanding of current childhood AML management in Japan.
• Identifies areas for future research and development in pediatric oncology.
• Aims to improve treatment efficacy, reduce long-term complications, and ultimately enhance patient survival rates in childhood AML.